anti-tumor activity
Halda’s HLD-0915 Shows Promising First-in-Human Results as a Safer RIPTAC Cancer Therapeutic
Halda Therapeutics; HLD-0915; RIPTAC; metastatic castration-resistant prostate cancer; first-in-human; safety; anti-tumor activity; oral therapeutic